The Report Covers the Global In-Vitro Diagnostics (IVD) Market is Segmented By Product (Reagents and Kits, Instruments), By Test Type (Clinical Chemistry, Molecular Diagnostics, Immunodiagnostics, Hematology, and Others), By Usability (Disposable IVD Devices, and Reusable IVD Devices), By Application (Infectious Disease, Diabetes, Cancer/Oncology, Cardiology, Autoimmune Disease, Nephrology, and Others), By End User (Hospitals Laboratories, Clinical Laboratories, Point-of-care Testing Centers, Academic Institutes, Patients, and Others), and Region Forecast 2019-2030. Key Players covered in this report are Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific, Danaher Corporation, Becton, Dickinson, and Company (BD), Bio-Rad Laboratories, Agilent Technologies, QIAGEN, Hologic, Cepheid, LumiraDx, and Roche Molecular Systems.

The market was valued at USD 90,400 million in 2025 and is anticipated to reach USD 146,500 million by 2035, expanding at a compound annual growth rate (CAGR) of 4.8% over the forecast period.

Metric	Value
Market Size (2025E)	USD 90,400 million
Market Value (2035F)	USD 146,500 million
CAGR (2025 to 2035)	4.8%

Country-wise Outlook

Country	CAGR (2025 to 2035)
United States	4.5%

Country	CAGR (2025 to 2035)
United Kingdom	4.2%

Region	CAGR (2025 to 2035)
European Union	4.3%

Country	CAGR (2025 to 2035)
Japan	4.4%

Country	CAGR (2025 to 2035)
South Korea	4.6%

Competitive Outlook

Company Name	Estimated Market Share (%)
Roche Diagnostics	20-24%
Abbott Laboratories	15-19%
Siemens Healthineers	12-16%
Danaher Corporation	10-14%
Other Companies (Combined)	30-40%

In vitro diagnostics market size is expected to grow from USD 108 billion in 2024 to USD 113 billion in 2025 and USD 190 billion by 2035, at a CAGR of 5.3%

In 2024, the global in-vitro diagnostics market had a revenue of almost 99 billion U.S. dollars. Between 2020 and 2021, the IVD market size increased significantly, going from around 76 billion U.S. dollars to just under 100 billion U.S. dollars.

The India In-Vitro Diagnostics (IVD) Market Report is Segmented by Test Type (Clinical Chemistry, and More), Technology (Polymerase Chain Reaction (PCR), and More), Product (Instruments, and More), Usability (Disposable IVD Devices, and More), Testing Site (Central Laboratory Testing, and More), Specimen Type (Blood, and More), Application, and End-User. The Market Forecasts are Provided in Terms of Value (USD).

The In Vitro Diagnostics Market size will exceed a valuation of USD 152.62 billion by 2034, to grow at a CAGR of 6.7% during the forecast period.

The In Vitro Diagnostics (IVD) market is projected to grow at a CAGR of 5-6%, driven by factors such as the increasing prevalence of chronic and infectious diseases, rising demand for personalised medicine, technological advancements enhancing diagnostic accuracy and efficiency, growing investments in healthcare infrastructure, and the shift towards non-invasive and rapid testing methods improving […]

The Latin America in-vitro diagnostics market grew a CAGR of 17.90% during the period 2025-2034. Analysis of human samples offers physicians with vital information to properly diagnose, treat, and prevent illnesses. Several leading companies offer in-vitro diagnostic (IVD) solutions that deliver rapid, sensitive results while minimizing cost and complexity. Modern in-vitro diagnostics (IVDs) enable better diagnosis for prevention and management of infectious and chronic diseases. In-vitro diagnostics can help identify early warning signs and individual risk factors, generating new openings for prevention and early intervention. Some in-vitro diagnostics range beyond the laboratory, hospital or doctor’s office, enabling patients with chronic illnesses to self-monitor and manage their own conditions. These factors are expected to drive market growth.

Global In Vitro Diagnostics market size is expected to reach $232.69 billion by 2029 at 11.8%, surging demand for self-administered tests reshapes the market landscape

Snapshot img

In-Vitro Diagnostics (IVD) Market Size 2025-2029

The in-vitro diagnostics (ivd) market size is forecast to increase by USD 28.8 billion at a CAGR of 4.6% between 2024 and 2029.

The market is experiencing significant growth, driven by the increasing geriatric population and the global adoption of advanced treatment solutions. The aging demographic trend is leading to a higher prevalence of chronic and infectious diseases, necessitating frequent diagnostic tests to ensure timely and accurate disease management. Moreover, the global healthcare industry's shift towards personalized medicine and precision diagnosis is fueling the demand for IVDs. However, the IVD Market's growth is not without challenges. Stringent regulatory bodies are guiding in-vitro diagnostics manufacturers to ensure product safety and efficacy. Compliance with these regulations adds to the manufacturing costs, making it essential for companies to adopt cost-effective production methods and streamlined supply chains. Additionally, the rapid technological advancements in diagnostics, such as molecular diagnostics and point-of-care testing, are intensifying competition in the market. Companies must continually innovate and differentiate their offerings to maintain their market position and capitalize on emerging opportunities.

What will be the Size of the In-Vitro Diagnostics (IVD) Market during the forecast period?

Request Free SampleThe market is experiencing significant growth due to various factors. Healthcare spending, driven by increasing tissues testing for disease diagnosis and personalized medicines, is a primary driver. Budget constraints in clinical laboratories have led to a preference for rapid tests and point-of-care devices. Techniques like liquid biopsy and molecular diagnostics are gaining traction in oncology and infectious diseases. Regulatory guidelines and economic downturns pose challenges, but the market continues to evolve. Preventive care testing and the rise of chronic diseases are expanding the market's scope. The use of bodily fluids in medical tests and the emergence of emerging economies are also contributing factors. Rapid diagnostic testing and specialized equipment are essential in the laboratory environment, particularly for disease diagnosis. Reimbursement scenarios and regulatory guidelines are critical considerations in the IVD market. The market's trends reflect the need for innovation and efficiency in healthcare, with a focus on meeting budget constraints and improving patient outcomes. The market's dynamics are shaped by the ongoing evolution of healthcare and the increasing importance of disease prevention and early diagnosis.

How is this In-Vitro Diagnostics (IVD) Industry segmented?

The in-vitro diagnostics (ivd) industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments. Product TypeReagents and kitsInstrumentsOthersTechnologyImmunoassayMolecular diagnosticsClinical chemistryHematologyOthersApplicationOncologyCardiologyAutoimmune diseasesNeurologyOthersEnd-userHospitals and clinicsResearch institutesDiagnostics laboratoriesOthersGeographyNorth AmericaUSCanadaEuropeFranceGermanyItalyUKMiddle East and AfricaAPACChinaIndiaJapanSouth AmericaBrazilRest of World (ROW)

By Product Type Insights

The reagents and kits segment is estimated to witness significant growth during the forecast period.Reagents and diagnostic kits play essential roles in the in vitro diagnostics (IVD) market, facilitating the detection and measurement of various analytes in patient samples. Reagents, as chemical substances, react with specific biological markers, enabling disease diagnosis and monitoring. Diagnostic kits, in turn, offer a complete solution for specific tests, often including reagents, calibrators, controls, and even instruments. In the realm of clinical chemistry, reagents are utilized to quantify substances like glucose, cholesterol, and enzymes in bodily fluids, contributing to the evaluation of medical conditions, such as diabetes and cardiovascular diseases. Molecular diagnostics, on the other hand, employ specialized reagents and kits to detect genetic mutations and proteins associated with diseases like cancer. Budget constraints and economic downturns have led to a growing preference for point-of-care (POC) testing, which allows for rapid, on-site diagnosis and reduces the need for expensive laboratory infrastructure. POC devices utilize reagents and kits to provide quick results for various applications, including infectious diseases, hematology, and immunodiagnostics. Personalized medicines and emerging markets, such as China and India, are driving demand for advanced diagnostic technologies, including companion diagnostics (CDx) and liquid biopsy. CDx, which util

The global infectious disease in-vitro diagnostics market will grow from US$44.5 Bn in 2024 to US$61.2 Bn by 2031, at a CAGR of 4.7% during the forecast period

The Mexico in-vitro diagnostics market grew a CAGR of 17.10% during the period 2025-2034. Analysis of human samples offers physicians with vital information to properly diagnose, treat, and prevent illnesses. Several leading companies offer in-vitro diagnostic (IVD) solutions that deliver rapid, sensitive results while minimizing cost and complexity. Modern in-vitro diagnostics (IVDs) enable better diagnosis for prevention and management of infectious and chronic diseases. In-vitro diagnostics can help identify early warning signs and individual risk factors, generating new openings for prevention and early intervention. Some in-vitro diagnostics range beyond the laboratory, hospital or doctor’s office, enabling patients with chronic illnesses to self-monitor and manage their own conditions. These factors are expected to drive market growth.

In Vitro Diagnostics Ivd Market is estimated to be valued at USD 126.73 Bn in 2025 and is expected to expand at CAGR of 6.5% reachingUSD 197.06 Bn by 2032

The Europe IVD market report segments the industry into By Test Type (Clinical Chemistry, Molecular Diagnostics, Hematology, and more), By Product (Instrument, Reagents, and more), By Usability (Disposable IVD Devices, and more), By Application (Infectious Disease, Diabetes, and more), By End User (Diagnostic Laboratories, and more) and Geography.

In Vitro Diagnostics Market Outlook

The global In Vitro Diagnostics (IVD) market size was valued at approximately $82 billion in 2023 and is projected to reach around $110 billion by 2032, growing at a compound annual growth rate (CAGR) of 3.2%. The market's growth is primarily driven by the rising prevalence of chronic diseases, increasing geriatric population, and advancements in diagnostic technologies.

The rising prevalence of chronic and infectious diseases globally is one of the key growth factors for the IVD market. Chronic conditions such as diabetes, cardiovascular diseases, and cancer require frequent diagnostic testing, which drives the demand for IVD products. Additionally, the recent COVID-19 pandemic underscored the importance of diagnostics in managing public health, further boosting the market. The increasing incidence of infectious diseases, including emerging and re-emerging infections, has also led to higher demand for rapid and accurate diagnostic tests.

Another significant growth factor is the growing geriatric population worldwide, which is more susceptible to various diseases. As the global population ages, the demand for diagnostic tests that can identify and manage age-related diseases is expected to rise. This demographic shift, coupled with an increase in healthcare expenditure, particularly in developed economies, supports the expansion of the IVD market. The elderly population often requires more frequent diagnostic testing, contributing to the market's sustained growth over the forecast period.

Technological advancements in the field of diagnostics have also played a crucial role in driving the market. Innovations such as next-generation sequencing, digital pathology, and AI-powered diagnostic tools have significantly enhanced the accuracy and efficiency of diagnostic tests. The integration of these advanced technologies in IVD products has led to improved disease detection and patient outcomes. Additionally, the development of point-of-care (POC) diagnostics has made it possible to conduct tests outside traditional laboratory settings, further boosting market growth.

In Vitro Diagnostics Devices have become a cornerstone in the healthcare industry, providing essential tools for disease detection and management. These devices encompass a wide range of equipment used to perform tests on samples such as blood, urine, and tissue. The evolution of these devices has been marked by significant technological advancements, enabling more precise and rapid diagnostics. As healthcare systems worldwide strive for efficiency and accuracy, the demand for state-of-the-art In Vitro Diagnostics Devices continues to rise. These devices not only improve patient outcomes by facilitating early detection but also support healthcare providers in making informed treatment decisions. The integration of digital technologies and automation in these devices further enhances their capabilities, making them indispensable in modern medical practice.

Regionally, North America holds the largest share of the IVD market, driven by high healthcare expenditure, well-established healthcare infrastructure, and the presence of major market players. Europe follows closely due to similar factors. However, the Asia Pacific region is expected to witness the fastest growth during the forecast period, supported by increasing healthcare investments, rising awareness about early disease diagnosis, and a growing patient population. The region's large population base and improving healthcare infrastructure present significant opportunities for market expansion.

Product Type Analysis

The IVD market by product type is segmented into instruments, reagents, software, and services. Instruments constitute a significant segment due to their essential role in conducting diagnostic tests. These include analyzers, automation systems, and point-of-care devices, which are critical for various diagnostic applications. The continuous advancements in instrumentation technology, such as the development of high-throughput systems and integrated platforms, are driving the growth of this segment. Moreover, the increasing adoption of automation in laboratories to enhance efficiency and reduce turnaround times is further propelling the demand for diagnostic instruments.

Reagents are another crucial segment within the IVD market, encompassing a wide range of chemical, biological, and immunological substances used in

As per Cognitive Market Research's latest published report, the Global In Vitro Diagnostics market size will be $87,826.93 Million by 2028.In Vitro Diagnostics Industry's Compound Annual Growth Rate will be 4.48% from 2023 to 2030.

North America In Vitro Diagnostics market size will be USD 30,196.36 Million by 2028.

What is Driving In Vitro Diagnostics Industry Growth?

Rise in the geriatric population

The rise in the adoption of advanced healthcare systems, new diagnostic techniques and adoption of medicines, have led to a significant decline in mortality rates, thereby accelerating the life expectancy.

Moreover, the early detection of the diseases and adoption of advanced diagnostic tools, including the over-the-counter diagnostic products, including glucose monitoring kits, are present in the market. These products are adopted by the elderly to reduce hospital visits.

Moreover, the development in the health care system, and early detection of diseases, and advanced treatment options, are some of the factors, which have extended the life expectancy, thereby leading to the rise in the geriatric population.

According to the World Health Organization (WHO), by 2050, the world’s population aged 60 years and above is expected to reach around 2 billion, that has increased from 900 million in 2015.

Additionally, according to the data published by UN, the global population aged 60 years or over numbered 962 million in 2017, has witnessed a significant rise, as large as in 1980 when there were 382 million geriatric people across the world.

The rise in the life expectancy is associated with the presence of several diseases, including the rise in the cardiovascular disease, diabetes, chronic low back pain is some of the factors, which have an inversely proportional rise in the demand for the invitro diagnostics.

Additionally, the immune system is affected owing to the rise in the age, which increases susceptibility to acquiring various diseases. Therefore, a significantly geriatric population needs access to advanced healthcare systems, especially for chronic diseases.

Therefore, the growth in the geriatric population is expected to increase the prevalence of various diseases across the globe. Thus, it is considered as one of the significant factors driving the growth of the invitro diagnostics market.

Restraints for In Vitro Diagnostics Market

High cost of devices and unfavorable reimbursement scenario’s.(Access Detailed Analysis in the Full Report Version)

Opportunities for In Vitro Diagnostics Market

Increasing R&D investments.(Access Detailed Analysis in the Full Report Version)

Introduction of In Vitro Diagnostics

A range of tools is used by health care practitioners to diagnose illnesses and guide treatment decisions. In-vitro diagnostics (IVDs), which are clinical tests that examine samples obtained from the human body, are among the most popular and commonly utilized.

In-vitro diagnostics are tests performed on samples obtained from the human body, such as blood or tissue. It can identify illnesses and other disorders, as well as monitor a person's general health to assist in the cure, treatment, or prevention of diseases.

IVDs are used to analyze human samples like blood and saliva, either by measuring the concentration of specific substances, or analytes (like sodium and cholesterol) or by detecting the presence or absence of a specific marker or set of markers, like a genetic mutation or an immune response to infection.

Precision medicine also employs in vitro diagnostics to identify patients who are likely to benefit from certain treatments or therapies. These in vitro diagnostics can involve next-generation sequencing tests, which analyze a person's DNA for genetic changes.

In-vitro diagnostics can be performed in laboratories, hospitals, or even at home. IVD tests are often conducted in a stand-alone laboratory, a hospital-based laboratory, or a point-of-care (POC) center, and typically comprise polymerase chain reaction (PCR), microarray methods, sequencing technologies, and mass spectrometry.

The tests themselves can be carried out on a wide range of tools, from simple portable devices to complicated laboratory equipment. It also made use of reagents that enable doctors to accurately diagnose patients and work to deliver suitable therapies.

Several...

In 2023, the In-Vitro Diagnostics (IVD) Market reached a value of USD 83.63 billion, and it is projected to surge to USD 114.02 billion by 2030.

This statistic describes the top 10 medical technology companies for in vitro diagnostics in 2017 and 2024, based on market share. In 2017, Sysmex accounted for 4.4 percent of the global market for in vitro diagnostics. By 2024, this share is expected to increase slightly to 4.5 percent. In vitro diagnostics allows for medical professionals to detect diseases, conditions, and infections. These tests can be conducted within a laboratory and sometimes at within a patient's home.

In 2020, the in vitro-diagnostics market is expected to be dominated by consumable products with a share of 70 percent. The statistic shows the estimated distribution of the global in-vitro diagnostics market in 2020 and a forecast for 2030, by type of product.

The global in-vitro diagnostics market size was worth over USD 97.36 billion in 2024 and is anticipated to see a CAGR exceeding 6.1%, reaching over USD 210.22 billion by 2037. The instruments segment is forecast to command the largest share, driven by faster detection of chronic diseases and genetic disorders.